JonesResearch downgraded Adaptimmune (ADAP) to Hold from Buy without a price target The firm cites the company’s capital overhang remaining as an ongoing concern for the downgrade. It awaits clarity on further financial strategies or partnerships for Adaptimmune.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune Therapeutics: Hold Rating Amid Financial Uncertainties and Strategic Challenges
- Adaptimmune price target lowered to $3 from $3.50 at H.C. Wainwright
- Adaptimmune Therapeutics: Balancing Positive Momentum with Strategic Pauses – A Hold Rating Analysis
- Adaptimmune price target lowered to $1.75 from $3 at Guggenheim
- Adaptimmune’s Earnings Call: TECELRA Success and Future Outlook